WO2008088030A1 - 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 - Google Patents
血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 Download PDFInfo
- Publication number
- WO2008088030A1 WO2008088030A1 PCT/JP2008/050554 JP2008050554W WO2008088030A1 WO 2008088030 A1 WO2008088030 A1 WO 2008088030A1 JP 2008050554 W JP2008050554 W JP 2008050554W WO 2008088030 A1 WO2008088030 A1 WO 2008088030A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- embolus
- thrombus
- prevention
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2675836A CA2675836C (en) | 2007-01-17 | 2008-01-17 | Composition for preventing or treating thrombus- or embolus-associated disease |
EP08703408.8A EP2119443B1 (en) | 2007-01-17 | 2008-01-17 | Composition for prevention or treatment of disease associated with thrombus or embolus |
JP2008554086A JP5345402B2 (ja) | 2007-01-17 | 2008-01-17 | 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 |
US12/523,407 US20100113506A1 (en) | 2007-01-17 | 2008-01-17 | Composition for preventing or treating thrombus- or embolus- associated disease |
ES08703408.8T ES2524320T3 (es) | 2007-01-17 | 2008-01-17 | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007008590 | 2007-01-17 | ||
JP2007-008590 | 2007-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008088030A1 true WO2008088030A1 (ja) | 2008-07-24 |
Family
ID=39636031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/050554 WO2008088030A1 (ja) | 2007-01-17 | 2008-01-17 | 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100113506A1 (ja) |
EP (1) | EP2119443B1 (ja) |
JP (1) | JP5345402B2 (ja) |
CA (1) | CA2675836C (ja) |
ES (1) | ES2524320T3 (ja) |
WO (1) | WO2008088030A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087938A1 (ja) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
WO2010021385A1 (ja) * | 2008-08-22 | 2010-02-25 | 持田製薬株式会社 | Anca関連血管炎治療薬 |
JP2012500385A (ja) * | 2008-08-06 | 2012-01-05 | インビトロックス,インコーポレイテッド | 生物学的応用における集束光散乱技術の使用 |
WO2012067152A1 (ja) * | 2010-11-16 | 2012-05-24 | 三菱化学株式会社 | Endothelial Protein C Receptor蛋白質による脳梗塞の検査方法 |
JPWO2011065444A1 (ja) * | 2009-11-27 | 2013-04-18 | 学校法人東海大学 | 抗血栓剤 |
WO2014003454A1 (en) * | 2012-06-28 | 2014-01-03 | Lg Life Sciences Ltd. | Oral dosage form product of clopidogrel hydrogen sulfate with improved stability |
JP2014531444A (ja) * | 2011-09-15 | 2014-11-27 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | 抗血小板療法に対する耐性を治療するか、逆転させるか、阻害するかまたは防止するための方法および組成物 |
JP2018521018A (ja) * | 2015-06-03 | 2018-08-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤 |
JP2020537696A (ja) * | 2017-10-18 | 2020-12-24 | 高麗製薬株式会社Korean Drug Co.,Ltd. | 野せり抽出物および抗血栓剤を含む抗血栓用組成物 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
PL2395991T3 (pl) | 2009-02-10 | 2013-11-29 | Amarin Pharmaceuticals Ie Ltd | Zastosowanie estru etylowego kwasu eikozapentaenowego do leczenia hipertriglicerydemii |
CN106822080A (zh) | 2009-04-29 | 2017-06-13 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
KR20170131722A (ko) | 2009-06-15 | 2017-11-29 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US11712429B2 (en) * | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
MY187464A (en) | 2012-06-29 | 2021-09-23 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
TN2021000013A1 (en) | 2018-09-24 | 2022-10-03 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
CN112967750B (zh) * | 2021-03-23 | 2024-03-29 | 复旦大学附属中山医院 | 一种预测氯吡格雷抗血小板疗效的模型及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08157362A (ja) | 1994-12-06 | 1996-06-18 | Sankyo Co Ltd | 油性物質含有固形製剤の製法 |
JPH08333243A (ja) | 1995-06-05 | 1996-12-17 | Nippon Kayaku Co Ltd | 口腔内感触の良好な錠剤 |
JPH1099046A (ja) | 1996-09-30 | 1998-04-21 | Nof Corp | 粉末組成物の製造方法 |
JP2005021124A (ja) | 2003-07-02 | 2005-01-27 | Kyukyu Yakuhin Kogyo Kk | 口腔用フィルム製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9125602D0 (en) * | 1991-12-02 | 1992-01-29 | Efamol Holdings | Method of preventing reocclusion of arteries |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
US7608640B2 (en) * | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
US20040242687A1 (en) * | 2001-09-26 | 2004-12-02 | Yoshikazu Kobayashi | Thrombus/thrombogenesis inhibitors |
EP1551382A4 (en) * | 2002-09-27 | 2007-01-24 | Martek Biosciences Corp | PROPHYLACTIC TREATMENT WITH DOCOSAHEXAENIC ACID FOR PATIENTS WITH SUBCLINIC INFLAMMATION |
AU2005272944B2 (en) * | 2004-08-13 | 2009-01-15 | Reva Medical, Inc. | Inherently radiopaque bioresorbable polymers for multiple uses |
WO2007098020A2 (en) * | 2006-02-16 | 2007-08-30 | Reliant Pharmaceuticals, Inc. | Methods of screening patients for omega-3 fatty acid therapy |
-
2008
- 2008-01-17 CA CA2675836A patent/CA2675836C/en active Active
- 2008-01-17 WO PCT/JP2008/050554 patent/WO2008088030A1/ja active Application Filing
- 2008-01-17 US US12/523,407 patent/US20100113506A1/en not_active Abandoned
- 2008-01-17 JP JP2008554086A patent/JP5345402B2/ja active Active
- 2008-01-17 EP EP08703408.8A patent/EP2119443B1/en active Active
- 2008-01-17 ES ES08703408.8T patent/ES2524320T3/es active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08157362A (ja) | 1994-12-06 | 1996-06-18 | Sankyo Co Ltd | 油性物質含有固形製剤の製法 |
JPH08333243A (ja) | 1995-06-05 | 1996-12-17 | Nippon Kayaku Co Ltd | 口腔内感触の良好な錠剤 |
JPH1099046A (ja) | 1996-09-30 | 1998-04-21 | Nof Corp | 粉末組成物の製造方法 |
JP2005021124A (ja) | 2003-07-02 | 2005-01-27 | Kyukyu Yakuhin Kogyo Kk | 口腔用フィルム製剤 |
Non-Patent Citations (10)
Title |
---|
"Iyakuhin Interview Form "Ko Kesshobanzai Plavix"", June 2006 (2006-06-01), pages 1 - 60, XP008119401 * |
DRUG INTERVIEW FORM OF THE ANTIPLATELET AGENT, June 2006 (2006-06-01), pages 43 |
ELG ET AL., THROMB. RES., vol. 101, no. 3, 2001, pages 159 - 170 |
GEIGER J. ET AL.: "Specific Impairment of Human Platelet P2YAC ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel", ARTERIOSCELEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 19, 1999, pages 2007 - 2011, XP001221745 * |
IKEDA Y.: "Junkankiyaku no Tsukaikata 2000 Sonoto no Junkankiyaku no Tsukaikata Ko Kesshoban'yaku", MEDICINA, vol. 37, no. 8, 2000, pages 1325 - 1328, XP008116828 * |
IKURO MARUYAMA, KEKKAN TO NAIHI, vol. 9, no. 6, 1999, pages 136 - 140 |
SATO M. ET AL.: "Effects of Highly Purified Ethyl All-cis-5,8-11,14,17-icosapentaenoate (EPA-E) on Rabbit Platelets", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 16, no. 4, 1993, pages 362 - 367, XP008116207 * |
See also references of EP2119443A4 |
YANAGISAWA K. ET AL.: "Ethyl Icosapentate to Ticlopidine no Heiyo Toyo ni Okeru Shukketsu Jikan to Kesshoban Gyoshuno ni Oyobosu Eikyo", CLINICAL REPORT, vol. 26, no. 7, 1992, pages 3193 - 3198, XP008116777 * |
YUKIO OZAKI, SAISHIN IGAKU, vol. 55, no. 2, pages 41 - 51 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087938A1 (ja) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
JP2012500385A (ja) * | 2008-08-06 | 2012-01-05 | インビトロックス,インコーポレイテッド | 生物学的応用における集束光散乱技術の使用 |
WO2010021385A1 (ja) * | 2008-08-22 | 2010-02-25 | 持田製薬株式会社 | Anca関連血管炎治療薬 |
EP2324827A1 (en) * | 2008-08-22 | 2011-05-25 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for anca-related vasculitis |
JPWO2010021385A1 (ja) * | 2008-08-22 | 2012-01-26 | 持田製薬株式会社 | Anca関連血管炎治療薬 |
EP2324827A4 (en) * | 2008-08-22 | 2012-04-25 | Mochida Pharm Co Ltd | THERAPEUTIC ACTIVE FOR ANCA-ASSOCIATED VASCULITIDES |
JPWO2011065444A1 (ja) * | 2009-11-27 | 2013-04-18 | 学校法人東海大学 | 抗血栓剤 |
WO2012067152A1 (ja) * | 2010-11-16 | 2012-05-24 | 三菱化学株式会社 | Endothelial Protein C Receptor蛋白質による脳梗塞の検査方法 |
JP2014531444A (ja) * | 2011-09-15 | 2014-11-27 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | 抗血小板療法に対する耐性を治療するか、逆転させるか、阻害するかまたは防止するための方法および組成物 |
WO2014003454A1 (en) * | 2012-06-28 | 2014-01-03 | Lg Life Sciences Ltd. | Oral dosage form product of clopidogrel hydrogen sulfate with improved stability |
JP2018521018A (ja) * | 2015-06-03 | 2018-08-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤 |
JP2022066207A (ja) * | 2015-06-03 | 2022-04-28 | ウィスコンシン アラムニ リサーチ ファンデーション | 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤 |
JP2020537696A (ja) * | 2017-10-18 | 2020-12-24 | 高麗製薬株式会社Korean Drug Co.,Ltd. | 野せり抽出物および抗血栓剤を含む抗血栓用組成物 |
JP2022062186A (ja) * | 2017-10-18 | 2022-04-19 | 高麗製薬株式会社 | 野せり抽出物および抗血栓剤を含む抗血栓用組成物 |
JP7339698B2 (ja) | 2017-10-18 | 2023-09-06 | 高麗製薬株式会社 | 野せり抽出物および抗血栓剤を含む抗血栓用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5345402B2 (ja) | 2013-11-20 |
EP2119443A1 (en) | 2009-11-18 |
JPWO2008088030A1 (ja) | 2010-05-13 |
EP2119443A4 (en) | 2010-03-03 |
US20100113506A1 (en) | 2010-05-06 |
EP2119443B1 (en) | 2014-08-20 |
ES2524320T3 (es) | 2014-12-05 |
CA2675836A1 (en) | 2008-07-24 |
CA2675836C (en) | 2016-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008088030A1 (ja) | 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 | |
IL259851A (en) | Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders | |
WO2011058474A8 (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
WO2007087431A3 (en) | Sublingual fentanyl spray | |
EP2340821A4 (en) | PROPHYLAXIS AGENTS / ADULTS OF ADULT DISEASES WITH 5-AMINOLEVULINIC ACID, A 5-AMINOLEVULIC ACID DERIVATIVE OR 5-AMINOLEVULIC ACID SALT OR 5-AMINOLEVULIC ACID DERIVATIVE AS AN ACTIVE SUBSTANCE | |
WO2007089652A3 (en) | Flavor-enhancing compositions, methods of manufacture, and methods of use | |
EP3626253A3 (en) | Stable formulations of linaclotide | |
WO2009017837A3 (en) | Sublingual fentanyl spray | |
WO2007042035A3 (en) | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders | |
WO2008006547A3 (en) | Pyrrolopyrimidines for pharmaceutical compositions | |
EP2103214A4 (en) | FLOOR OR SEED TREATMENT AGENT CONTAINING A CHINOLINE COMPOUND OR A SALT THEREOF AS ACTIVE SUBSTANCE OR METHOD FOR COMBATING PLANT DISEASES USING THE AGENT | |
WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
WO2008022974A3 (fr) | Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites | |
EP2153834A3 (en) | Extended release pharmaceutical compositions comprising quetiapine salts | |
WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
WO2009066315A3 (en) | Sustained release compositions of trimetazidine and process for preparation thereof | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2009102443A3 (en) | Octanoic acid formulations and methods of treatment using the same | |
WO2008001201A3 (en) | Pharmaceutical compositions of clopidogrel | |
EP3915566A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE, CONTAINING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT | |
WO2011070318A3 (en) | Topical formulation | |
WO2008026048A3 (en) | Stable injectable pharmaceutical compositions of docetaxel | |
WO2009060952A1 (ja) | 新規製剤 | |
EP2392335A3 (en) | Use of 24-norUDCA | |
WO2006127319A3 (en) | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08703408 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008554086 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2675836 Country of ref document: CA Ref document number: 12523407 Country of ref document: US Ref document number: 2008703408 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |